Abstract
Ceftolozane-tazobactam is a cephalosporin-β-lactamase inhibitor combination that exhibits potent in vitro activity against Pseudomonas aeruginosa, including strains that are resistant to other β-lactams. The emergence of ceftolozane-tazobactam resistance among clinical isolates of P. aeruginosa has rarely been described. Here we characterized ceftolozane-tazobactam-resistant P. aeruginosa strains recovered from a patient who was treated with this agent for 6 weeks for a recurrent wound infection. The results showed that the resistance was mediated by a single AmpC structural mutation.
Keywords:
AmpC; G183D; Pseudomonas aeruginosa; ceftolozane-tazobactam.
Copyright © 2017 American Society for Microbiology.
MeSH terms
-
Aged
-
Anti-Bacterial Agents / therapeutic use*
-
Bacterial Proteins / genetics*
-
Cephalosporins / therapeutic use*
-
Drug Resistance, Multiple, Bacterial / genetics*
-
Humans
-
Male
-
Microbial Sensitivity Tests
-
Multilocus Sequence Typing
-
Penicillanic Acid / analogs & derivatives*
-
Penicillanic Acid / therapeutic use
-
Polymorphism, Single Nucleotide / genetics
-
Pseudomonas Infections / drug therapy*
-
Pseudomonas aeruginosa / drug effects*
-
Pseudomonas aeruginosa / genetics*
-
Tazobactam
-
Wound Infection / drug therapy
-
Wound Infection / microbiology
-
beta-Lactamase Inhibitors / therapeutic use*
-
beta-Lactamases / genetics*
Substances
-
Anti-Bacterial Agents
-
Bacterial Proteins
-
Cephalosporins
-
beta-Lactamase Inhibitors
-
ceftolozane, tazobactam drug combination
-
Penicillanic Acid
-
AmpC beta-lactamases
-
beta-Lactamases
-
Tazobactam